| Gastric cancer stem cells: evidence, potential markers, and clinical implications D Brungs, M Aghmesheh, KL Vine, TM Becker, MG Carolan, M Ranson Journal of gastroenterology 51, 313-326, 2016 | 139 | 2016 |
| The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis D Brungs, J Chen, M Aghmesheh, KL Vine, TM Becker, MG Carolan, ... Oncotarget 8 (14), 23099, 2017 | 56 | 2017 |
| Sidedness is prognostic in locoregional colon cancer: an analysis of 9509 Australian patients D Brungs, M Aghmesheh, P de Souza, W Ng, W Chua, M Carolan, ... BMC cancer 17, 1-9, 2017 | 47 | 2017 |
| Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an … CJ Sweeney, AJ Martin, MR Stockler, S Begbie, L Cheung, KN Chi, ... The Lancet Oncology 24 (4), 323-334, 2023 | 46 | 2023 |
| Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma K Connolly, D Brungs, E Szeto, RJ Epstein Current Oncology 21 (1), e151, 2014 | 46 | 2014 |
| Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis D Brungs, J Chen, P Masson, RJ Epstein Prostate Cancer and Prostatic Diseases 17 (2), 105-111, 2014 | 41 | 2014 |
| Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations M Wang, JCH Yang, PL Mitchell, J Fang, DR Camidge, W Nian, CH Chiu, ... Cancer discovery 12 (7), 1676-1689, 2022 | 40 | 2022 |
| Establishment of novel long-term cultures from EpCAM positive and negative circulating tumour cells from patients with metastatic gastroesophageal cancer D Brungs, E Minaei, AK Piper, J Perry, A Splitt, M Carolan, S Ryan, XJ Wu, ... Scientific reports 10 (1), 539, 2020 | 36 | 2020 |
| The role of liquid biopsies in detecting molecular tumor biomarkers in brain cancer patients H Sareen, C Garrett, D Lynch, B Powter, D Brungs, A Cooper, J Po, ... Cancers 12 (7), 1831, 2020 | 34 | 2020 |
| Safety and efficacy of oxaliplatin doublet adjuvant chemotherapy in elderly patients with stage III colon cancer D Brungs, M Aghmesheh, P de Souza, M Carolan, P Clingan, J Rose, ... Clinical colorectal cancer 17 (3), e549-e555, 2018 | 29 | 2018 |
| Human TERT promoter mutations as a prognostic biomarker in glioma B Powter, SA Jeffreys, H Sareen, A Cooper, D Brungs, J Po, T Roberts, ... Journal of cancer research and clinical oncology 147, 1007-1017, 2021 | 28 | 2021 |
| Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: a systematic review and meta-analysis AR Hayes, D Brungs, N Pavlakis PloS one 13 (1), e0191455, 2018 | 28 | 2018 |
| Cryopreservation for delayed circulating tumor cell isolation is a valid strategy for prognostic association of circulating tumor cells in gastroesophageal cancer D Brungs, D Lynch, AWS Luk, E Minaei, M Ranson, M Aghmesheh, ... World journal of gastroenterology 24 (7), 810, 2018 | 25 | 2018 |
| Central venous catheter thrombosis in cancer: a multi-centre retrospective study investigating risk factors and contemporary trends in management L Haggstrom, G Parmar, D Brungs Clinical Medicine Insights: Oncology 14, 1179554920953097, 2020 | 22 | 2020 |
| Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status JW Po, Y Ma, B Balakrishna, D Brungs, F Azimi, P de Souza, TM Becker PLoS One 14 (2), e0211866, 2019 | 18 | 2019 |
| OA15. 02 Phase 1 studies of DZD9008, an oral selective EGFR/HER2 inhibitor in advanced NSCLC with EGFR exon20 insertion mutations P Janne, M Wang, P Mitchell, J Fang, W Nian, C Chiu, J Zhou, Y Zhao, ... Journal of Thoracic Oncology 16 (10), S874, 2021 | 14 | 2021 |
| Comparison of peripheral blood mononuclear cell isolation techniques and the impact of cryopreservation on human lymphocytes expressing CD39 and CD73 RJ Turner, NJ Geraghty, JG Williams, D Ly, D Brungs, MG Carolan, ... Purinergic Signalling 16 (3), 389-401, 2020 | 14 | 2020 |
| Retrospective evaluation of the use of Pembrolizumab in malignant mesothelioma in a real-world Australian population T Ahmadzada, WA Cooper, M Holmes, A Mahar, H Westman, AJ Gill, ... JTO Clinical and Research Reports 1 (4), 100075, 2020 | 12 | 2020 |
| Expression of cancer stem cell markers is prognostic in metastatic gastroesophageal adenocarcinoma D Brungs, A Lochhead, A Iyer, M Illemann, P Colligan, NG Hirst, A Splitt, ... Pathology 51 (5), 474-480, 2019 | 11 | 2019 |
| Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD (L) 1 treatment failures. PA Janne, M Wang, DR Camidge, P Mitchell, J Fang, W Nian, CH Chiu, ... Journal of Clinical Oncology 40 (16_suppl), 9015-9015, 2022 | 9 | 2022 |
